The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)
Recruiting now
Conditions studied: Migraine
In brief
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)
Key facts
- Study ID
- NCT06628921
- Run by
- University of Florence
- People needed
- 50
- Starts
- 2024-10-30
- Expected to finish
- 2026-10-30
- Last updated by the study team
- 2026-01-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III).
- At least 8 days of migraine per month.
- Adequate compliance with study procedures.
- Availability of a migraine diary for at least one month prior to enrollment.
- Ongoing attack before administration.
- Included in the TACHIS study (NCT06409845)
You may not qualify if…
- Subjects with contraindications to the use of eptinezumab.
- Concomitant diagnosis of medical conditions and/or comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes.
- Pregnancy and breastfeeding.
- Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab.
Where it is running
- Campus Biomedico — Roma, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.